Related Experiment Video
Updated: Jul 2, 2026
08:21
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Current Options for Kidney Protection: Are Renin-Angiotensin System Inhibitors Still Relevant?
1Boston, Massachusetts.
Seminars in Nephrology
|June 30, 2026
Summary
Renin-angiotensin-aldosterone system (RAAS) inhibition remains crucial for slowing chronic kidney disease progression. Newer therapies complement RAAS inhibitors, offering enhanced kidney and cardiovascular benefits.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- Chronic kidney disease (CKD) involves complex mechanisms like hemodynamic stress, proteinuria, inflammation, fibrosis, and metabolic issues.
- Barry Brenner's hyperfiltration hypothesis identified these as key drivers of kidney injury.
- Renin-angiotensin-aldosterone system (RAAS) inhibition revolutionized CKD treatment by slowing progression and improving outcomes.
Purpose of the Study:
- To review the evolution of CKD treatment strategies.
- To highlight the enduring role of RAAS inhibitors and the emergence of new therapeutic classes.
- To discuss advancements in CKD prognostic assessment.
Main Methods:
- Literature review of landmark trials and therapeutic advancements in CKD.
- Analysis of the role of RAAS inhibition in kidney protection.
- Examination of novel therapeutic agents and prognostic tools.
Main Results:
- RAAS inhibitors are a cornerstone of CKD management, significantly slowing disease progression.
- Newer therapeutic classes offer additional kidney and cardiovascular benefits.
- Prognostic assessment has advanced with biomarkers, genetics, imaging, and digital tools, but clinical integration is ongoing.
Conclusions:
- RAAS inhibitors remain essential for kidney protection in CKD.
- Emerging therapies complement, rather than replace, established RAAS inhibitor treatments.
- Integrated prognostic tools are needed for comprehensive CKD management.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:20Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...